Market Watch: FDA Approves Pfizer COVID-19 Booster for Age 12 To 15

FDA Approves Pfizer COVID-19 Booster for Age 12 To 15

For children aged 12 to 15, the FDA has approved the use of a third dosage of the Pfizer Inc (NYSE: PFE) and BioNTech SE BNTX COVID-19 vaccine.

For people aged 12 and up, the interval between primary doses and booster shots has been shortened to 5 months from 6 months.

The third shot has also been approved by the FDA for immunocompromised children aged 5 to 11.

The FDA said it analyzed published data and real-world evidence given by the Israeli Ministry of Health on the safety of booster doses, including data from nearly 6,300 people aged 12 to 15 who got a Pfizer shot.

Related:  Pre-market Stock Watch: Top Gainers and Losers on Monday

Price Action: During the market session on the last check Monday, PFE shares were down 3.22 percent at $57.15, and BNTX stock was down 4.97 percent at $245.

The Author

Oladotun Olayemi

Dotun is a financial enthusiast who specializes in first-in-class financial content, including crypto, blockchain, market, and business, to educate and inform readers.